Abstract:Introduction: During HIV infection the severe depletion of intestinal CD4 T-cells is associated with microbial translocation, systemic immune activation, and disease progression. This study examined intestinal and peripheral CD4 T-cell subsets reconstitution under combined antiretroviral therapy (cART), and systemic immune activation markers. Methods: This longitudinal single-arm pilot study evaluates CD4 T cells, including Th1 and Th17, in gut and blood and soluble markers for inflammation in HIV-infected individuals before (M0) and after eight (M8) months of cART. From January 2010 to December 2011, 10 HIV-1 naı̈ve patients were screened and 9 enrolled. Blood and gut CD4 T-cells subsets and cellular immune activation were determined by flow-cytometry and plasma soluble CD14 by ELISA. CD4 Th17 cells were detected in gut biopsies by immunohistochemistry. Microbial translocation was measured by limulus-amebocyte-lysate assay to detect bacterial lipopolysaccharide (LPS) and PCR Real Time to detect plasma bacterial 16S rDNA. Results: Eight months of cART increased intestinal CD4 and Th17 cells and reduced levels of T-cell activation and proliferation. The magnitude of intestinal CD4 T-cell reconstitution correlated with the reduction of plasma LPS. Importantly, the magnitude of Th17 cells reconstitution correlated directly with blood CD4 T-cell recovery. Conclusion: Short-term antiretroviral therapy resulted in a significant increase in the levels of total and Th17 CD4 T-cells in the gut mucosa and in decline of T-cell activation. The observation that pre-treatment levels of CD4 and of CD8 T-cell activation are predictors of the magnitude of Th17 cell reconstitution following cART provides further rationale for an early initiation of cART in HIV-infected individuals. Trial Registration: ClinicalTrials.gov NCT02097381 Citation: d’Ettorre G, Baroncelli S, Micci L, Ceccarelli G, Andreotti M, et al. (2014) Reconstitution of Intestinal CD4 and Th17 T Cells in Antiretroviral Therapy Suppressed HIV-Infected Subjects: Implication for Residual Immune Activation from the Results of a Clinical Trial. PLoS ONE 9(10): e109791. doi:10.1371/journal. pone.0109791 Editor: Francesca Ceccherini-Silberstein, University of Rome Tor Vergata, Italy Received April 13, 2014; Accepted September 4, 2014; Published October 23, 2014 Copyright: 2014 d’Ettorre et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Data Availability: The authors confirm that all data underlying the findings are fully available without restriction. All relevant data are within the paper, anyway the complete database is freely available from the archive of Department of Public Health and Infectious Diseases of University of Rome ‘‘Sapienza’’ (Italy). This is because the Italian law on privacy does not allow the online publication of complete databases with sensitive data. All data are available upon request contacting Dr. Gabriella d’Ettorre MD PhD. Department of Public Health and Infectious Diseases. Viale del Policlinico 155 (00161) Rome (Italy). Tel 0039-06-49970313, fax 0039-06-49972625, email gabriella.dettorre@uniroma1.it. Funding: This work was supported by ISS ‘‘Programma Italia Usa’’ (to AM) and by National Institutes of Health grant R01-AI-084836 (to MP). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. Competing Interests: The authors have declared that no competing interests exist. * Email: gabriella.dettorre@uniroma1.it PLOS ONE | www.plosone.org 1 October 2014 | Volume 9 | Issue 10 | e109791

Patients' characteristics and clinical implications of suboptimal CD4 T-cell gains after 1 year of successful antiretroviral therapy

Clinical outcome of HIV-infected patients with sustained virologic response to antiretroviral therapy: long-term follow-up of a multicenter cohort

Failure of CD4+ T-cell Recovery upon Virally-Effective cART: an Enduring Gap in the Understanding of HIV+ Immunological non-Responders

Is weak CD4+ gain in the course of suppressive combination antiretroviral therapy for HIV infection a current clinical challenge? A case report and brief review of the literature

CD4 recovery is associated with genetic variation in IFNγ and IL19 genes

The persistence of low CD4/CD8 ratio in chronic HIV-infection, despite ART suppression and normal CD4 levels, is associated with pre-therapy values of inflammation and thymic function

The Factors Related To Cd4+T-Cell Recovery And Viral Suppression In Patients Who Have Low Cd4+T Cell Counts At The Initiation Of Haart: A Retrospective Study Of The National Hiv Treatment Sub-Database Of Zhejiang Province, China, 2014

Determinants of suboptimal CD4+ T cell recovery after antiretroviral therapy initiation in a prospective cohort of acute HIV-1 infection

Clinical outcomes and risk factors for immune recovery and all‐cause mortality in Latin Americans living with HIV with virological success: a retrospective cohort study

Increased ex vivo cell death of central memory CD4 T cells in treated HIV infected individuals with unsatisfactory immune recovery

High circulating SDF-1and MCP-1 levels and genetic variations in CXCL12, CCL2 and CCR5: Prognostic signature of immune recovery status in treated HIV-positive patients

Immunological recovery failure in cART-treated HIV-positive patients is associated with reduced thymic output and RTE CD4+ T cell death by pyroptosis

Pre-cART Elevation of CRP and CD4+ T-Cell Immune Activation Associated With HIV Clinical Progression in a Multinational Case-Cohort Study

Reconstitution of Intestinal CD 4 and Th 17 T Cells in Antiretroviral Therapy Suppressed HIV-Infected Subjects : Implication for Residual Immune Activation from the Results of a Clinical Trial

The Risk Factors for Suboptimal CD4 Recovery in HIV Infected Population: an Observational and Retrospective Study in Shanghai, China.

Impaired gut junctional complexes feature late-treated individuals with suboptimal CD4+ T-cell recovery upon virologically suppressive combination antiretroviral therapy

Effective Treatment of Patients Experiencing Primary, Acute HIV Infection Decreases Exhausted/Activated CD4+ T Cells and CD8+ T Memory Stem Cells

Plasma Human Immunodeficiency Virus 1 RNA and CD4+ T-Cell Counts Are Determinants of Virological Nonsuppression Outcomes With Initial Integrase Inhibitor-Based Regimens: A Prospective RESPOND Cohort Study

Determinants of CD4+ T Cell Recovery During Suppressive Antiretroviral Therapy: Association of Immune Activation, T Cell Maturation Markers, and Cellular HIV-1 DNA.

Incomplete recovery of the CD4+/CD8+ ratio is associated with the late introduction of antiretroviral therapy among people living with HIV infection

Plasma concentrations of IL-6, MIP-1β, IP-10, and PTX-3 as predictors of the immunological response to antiretroviral treatment in people with HIV